The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 16; no. 4; pp. 255 - 266
• Main Author: Dézsi, Csaba András
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2016; Springer Nature B.V
• Subjects: Aldosterone - metabolism; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Animals; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Blood Pressure - drug effects; Cardiology; Cerebrovascular Disorders - drug therapy; Cerebrovascular Disorders - metabolism; Humans; Hypertension - drug therapy; Hypertension - metabolism; Medicine; Medicine & Public Health; Pharmacology/Toxicology; Pharmacotherapy; Renal Insufficiency, Chronic - drug therapy; Renal Insufficiency, Chronic - metabolism; Renin-Angiotensin System - drug effects; Review; Review Article; Erectile Dysfunction; Chronic Kidney Disease; Serum Uric Acid; Valsartan; Losartan
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/s40256-016-0165-4

The renin–angiotensin–aldosterone system plays an important role in the pathophysiology of hypertension and is closely related with cardio- and cerebrovascular events and chronic kidney diseases. Each angiotensin receptor blocker (ARB) is important in the treatment of hypertension, according to the results of recent years. This is a practical review of the available evidence on the different benefits of ARBs beyond their blood pressure-lowering effect, with an emphasis on the differences found between the particular compounds and the therapeutic implications of the findings, with specific reference to the co-morbidities.